Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert A Branch

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Drug Metabolism Reviews|December 14, 2016
Drug metabolism and liver disease: a drug-gene-environment interactionNathalie K Zgheib, Robert A Branch
British Journal of Clinical Pharmacology|February 20, 2002
Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjectsReginald F Frye, Robert A Branch
Digestive Diseases and Sciences|March 19, 2010
HCC in older patientsBrian I Carr, Petr Pancoska, Robert A Branch
Hepato-Gastroenterology|November 2, 2010
Significance of increased serum GGTP levels in HCC patientsBrian I Carr, Petr Pancoska, Robert A Branch
Seminars in Oncology|May 25, 2010
Network-based analysis of survival for unresectable hepatocellular carcinomaPetr Pancoska, Brian I Carr, Robert A Branch
Hepatology International|March 23, 2010
Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort studyBrian I Carr, Petr Pancoska, Robert A Branch
Journal of Gastroenterology and Hepatology|August 28, 2010
Low alpha-fetoprotein hepatocellular carcinomaBrian I Carr, Petr Pancoska, Robert A Branch
Hepato-Gastroenterology|August 12, 2010
HCC in young adultsBrian I Carr, Petr Pancoska, Robert A Branch
Hepatology International|August 12, 2009
Gender-based outcomes differences in unresectable hepatocellular carcinomaShama C Buch, Venkateswarlu Kondragunta, Robert A Branch, et al.
Cancer|January 13, 2010
Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort studyBrian I Carr, Venkateswarlu Kondragunta, Shama C Buch, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Drug Metabolism Reviews|December 14, 2016
Drug metabolism and liver disease: a drug-gene-environment interactionNathalie K Zgheib, Robert A Branch
British Journal of Clinical Pharmacology|February 20, 2002
Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjectsReginald F Frye, Robert A Branch
Digestive Diseases and Sciences|March 19, 2010
HCC in older patientsBrian I Carr, Petr Pancoska, Robert A Branch
Hepato-Gastroenterology|November 2, 2010
Significance of increased serum GGTP levels in HCC patientsBrian I Carr, Petr Pancoska, Robert A Branch
Seminars in Oncology|May 25, 2010
Network-based analysis of survival for unresectable hepatocellular carcinomaPetr Pancoska, Brian I Carr, Robert A Branch
Hepatology International|March 23, 2010
Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort studyBrian I Carr, Petr Pancoska, Robert A Branch
Journal of Gastroenterology and Hepatology|August 28, 2010
Low alpha-fetoprotein hepatocellular carcinomaBrian I Carr, Petr Pancoska, Robert A Branch
Hepato-Gastroenterology|August 12, 2010
HCC in young adultsBrian I Carr, Petr Pancoska, Robert A Branch
Hepatology International|August 12, 2009
Gender-based outcomes differences in unresectable hepatocellular carcinomaShama C Buch, Venkateswarlu Kondragunta, Robert A Branch, et al.
Cancer|January 13, 2010
Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort studyBrian I Carr, Venkateswarlu Kondragunta, Shama C Buch, et al.
Pageof 3